A. D. de Goede

发表

Blood Flow Remodels Growing Vasculature During Vascular Endothelial Growth Factor Gene Therapy and Determines Between Capillary Arterialization and Sprouting Angiogenesis

S. Ylä-Herttuala, O. Gröhn, T. Liimatainen, 2005, Circulation.

Induction of humoral and cellular immune responses by antigen-expressing immunostimulatory liposomes.

G. Rimmelzwaan, E. Mastrobattista, M. Amidi, 2012, Journal of controlled release : official journal of the Controlled Release Society.

Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients

C. Figdor, R. Koornstra, S. Croockewit, 2021, Oncoimmunology.

Convection Enhanced Delivery of the Oncolytic Adenovirus Delta24-RGD in Patients with Recurrent GBM: A Phase I Clinical Trial Including Correlative Studies

R. Vernhout, A. Kleijn, M. Lamfers, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.

A. Osterhaus, G. Rimmelzwaan, L. Dekker, 2009, Vaccine.

A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.

P. Eilers, A. Osterhaus, J. Aerts, 2012, Clinical immunology.

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

J. Witjes, C. Figdor, J. Barentsz, 2019, Journal of Immunotherapy for Cancer.

DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift.

Maarten A. Bijl, J. Aerts, A. Osterhaus, 2015, Vaccine.

Understanding HIV infection for the design of a therapeutic vaccine. Part I: Epidemiology and pathogenesis of HIV infection.

A. Osterhaus, A. Vulto, R. Gruters, 2015, Annales pharmaceutiques francaises.

Understanding HIV infection for the design of a therapeutic vaccine. Part II: Vaccination strategies for HIV.

A. Osterhaus, A. Vulto, R. Gruters, 2015, Annales pharmaceutiques francaises.

HIV-1 evolution in patients undergoing immunotherapy with Tat, Rev, and Nef expressing dendritic cells followed by treatment interruption

P. Lemey, A. Osterhaus, J. Aerts, 2013, AIDS.

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

C. Figdor, C. Punt, R. Koornstra, 2020, Cancer Immunology, Immunotherapy.

Automated compounding technology and workflow solutions for the preparation of chemotherapy: a systematic review

S. Batson, M. Canobbio, S. Mitchell, 2019, European journal of hospital pharmacy : science and practice.

What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.

Jarno Hoekman, Marcel H N Hoefnagel, Gerty Schreibelt, 2020, Cytotherapy.

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients

C. Figdor, J. Keunen, C. Punt, 2015, Journal of Immunotherapy for Cancer.

Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemia

J. Jansen, T. Fehniger, H. Dolstra, 2023, Cancer Immunology, Immunotherapy.

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

N. Naus, A. de Klein, W. Gerritsen, 2016, Ophthalmology.

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Inge M. N. Wortel, J. Bonenkamp, W. Gerritsen, 2024, Nature communications.

Design of TOLERANT: phase I/II safety assessment of intranodal administration of HSP70/mB29a self-peptide antigen-loaded autologous tolerogenic dendritic cells in patients with rheumatoid arthritis.

F. Broere, A. J. Stoppelenburg, B. Koeneman, 2024, BMJ open.